Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy

Vertex and CRISPR Therapeutics Announce Authorization of the ...

CASGEVY™ is a genetically modified autologous CD34+ cell enriched population that contains human hematopoietic stem and progenitor cells edited ex vivo by ...

Vertex and CRISPR Therapeutics Announce US FDA Approval of ...

CASGEVY is a one-time therapy used to treat people aged 12 years and older with sickle cell disease (SCD) who have frequent vaso-occlusive ...

Therapies - CRISPR Therapeutics

CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in ...

Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy - Time

Find out why Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy is one of the best inventions of 2024.

Vertex and CRISPR Therapeutics Complete Submission of Rolling ...

The completion of the rolling Biologics License Applications (BLAs) to the US Food and Drug Administration (FDA) for the investigational treatment ...

FDA Approves First Gene Therapies to Treat Patients with Sickle ...

Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. ... The FDA granted approval of Casgevy to ...

Vertex taps Lonza to help produce global supply of cutting-edge ...

Casgevy, which Vertex shares with CRISPR Therapeutics, made history late last year when it picked up approvals, first in the U.K. and then in ...

Vertex, CRISPR's Casgevy Highlights Complex Path to Gene ...

CRISPR Therapeutics and Vertex Pharmaceuticals are a great example. The companies made history last year when they achieved the first approval ...

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited ...

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and ...

Press Release - CRISPR Therapeutics

CASGEVY is a collaboration product between CRISPR Therapeutics and Vertex Pharmaceuticals, and as part of an amendment to the collaboration ...

Canada Approves Vertex and CRISPR Therapeutics' Gene Therapy ...

Canada Approves Vertex and CRISPR Therapeutics' Gene Therapy Casgevy for Sickle Cell Disease and TDT ... Vertex Pharmaceuticals' and CRISPR ...

The world's first CRISPR therapy is approved: who will receive it?

Casgevy (exagamglogene autotemcel) is a first-of-its-kind treatment made by Vertex Pharmaceuticals and CRISPR Therapeutics in Zug, Switzerland.

Vertex Announces US FDA Approval of CASGEVY ...

CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene ... medicines, including a conditioning medicine, as part of your treatment with CASGEVY.

CASGEVY® (exagamglogene autotemcel) | Patient Website

CASGEVY word mark and design are registered trademarks of Vertex Pharmaceuticals Incorporated. CRISPR THERAPEUTICS word mark and design are registered ...

Patients At Last Begin Receiving Vertex-CRISPR and Bluebird ...

... Vertex Pharmaceuticals and CRISPR Therapeutics' sickle cell gene therapy Casgevy. But infusions have since begun, a spokesperson for Vertex ...

European Commission Approves First CRISPR/Cas9…

CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient's own ...

Vertex's Casgevy launch progresses as CF business posts ...

While cystic fibrosis has long been Vertex Pharmaceuticals' bread and butter, the company has been eager to diversify its revenue base in ...

CRISPR therapy for sickle cell approved by FDA in gene editing ...

Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is the first medicine based on the Nobel Prize-winning technology to be ...

Press Release - CRISPR Therapeutics

CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient's own ...

Vertex Connects Patient Support - Casgevy

CASGEVY is a one-time therapy used to treat people aged 12 years and older with sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs.